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Dosimetry for treatment planning of LDR prostate brachytherapy relies on:
• air kerma strength calibration of sources, SK
(traceable to a primary standard) 
• a Monte Carlo generated, relative dose rate matrix (per unit SK)
(independently verified experimentally)
DeWerd et al. Med. Phys. 38 (2011)
MC type B uncertainties:
1. Source Construction
2. Movable components
3. Source emissions
4. Phantom geometry
5. Phantom composition
6. Radiation transport code
7. Interaction and scoring cross sections
8. Scoring algorithms and uncertainties
Accounting for MC type B uncertainties arising 
from uncertainty of the seed geometry is recommended 
in the updates of TG43 as well as AAPM/ESTRO TG-138
DeWerd et al. Med. Phys. 38 (2011):
“A sophisticated MC dosimetric analysis 
would simulate the influence of varying each 
of these components and estimate the 
resultant effect of these uncertainties on the 
calculated dose distribution.”
The manufacturer stated tolerance of 5 construction parameters 
were considered for a commercially available seed 
Parameter Nominal value,xi (mm)
Uncertainty,
uxi (mm)*
Radioactive Silver-Halide layer thickness 0.003 0.001
Cylindrical Silver rod length 3.4 0.05
Cylindrical Silver rod diameter 0.51 0.02
Titanium tube length 4.5 0.01
Titanium tube diameter / weld diameter 0.8 0.05
*calculated assuming normal distribution of parameters within tolerance
Materials and methods
• Let the 2D relative dose rate distribution on a plane including the source long axis.
• Using MCNP5 v.1.40, 2 MC runs (water and air) were performed for the set of nominal values
of source construction parameters xi to obtain fnom.
• Assuming f is approximately linear and no xi correlation exists, the total geometric uncertainty,
ugeo , can be calculated according to the law of uncertainty propagation:
• The partial derivatives were approximated by the forward and backward finite differences.
Each xi was individually changed to xi+uxi or xi-uxi and MC runs were performed to obtain f+,i and f-,i 
respectively.
Then:
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Single source results Sk
Parameter, xi SK nom (U) ·10-4 SK +,i (U)·10-4 SK -,i (U) ·10-4
Radioactive Silver-Halide layer thickness
2.4276
2.4210 2.4346
Cylindrical Silver rod length 2.4292 2.4259
Cylindrical Silver rod diameter 2.4086 2.4453
Titanium tube length 2.4275 2.4275
Titanium tube diameter / weld diameter 2.0230 2.9446
• SK exhibits a 38 % variation due to construction tolerance
• this underlines the importance of source SK calibration
• we are concerned with the uncertainty of in the MC data set in the
clinical TPS
kS
Df


Single source results
MC Type A %u %ugeo for {xi + uxi} %ugeo for {xi - uxi}
• Radioactive coating thickness, end weld radius major uncertainty contributors
• uncertainties position dependant 
• 0.2% compared to DeWerd et al. @ (1, 90)
• %ugeo for {xi - uxi} was adopted as a worst case scenario
Results in clinical LDR prostate brachytherapy plans
Patient plans were exported in dicom-RT.
The superposition principle was used to generate the 3D dose distribution.
ugeo from the implanted sources was combined in quadrature at each point of the 3D dose 
distribution.
Small / 65 dwell positions (default) Large / 89 dwell positions
Results in clinical LDR prostate brachytherapy plans
DVH differences < 0.1% on D90
Small / 65 dwell positions (default) Large / 89 dwell positions
Discussion
• Specific source model 125I LDR brachytherapy applications 
• Total MC uncertainties typeA + type B (statistics, photoionization, cross sections, 
source energy spectrum, seed geometry,…) 
of about 1.7%1 to 2.5%2
• Clinical dosimetric uncertainties (inter-seed attenuation 2%-5% reduction of D90,3
heterogeneities 3%, 4% on D90,3 seed localization
uncertainty <5%,4 anatomy changes between dose
delivery and post-implant imaging 5%,5 …) ~ 11%
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5. Yue et al. Med.Phys. 26 (1999)
Conclusions
• Although source construction uncertainties are not the major source of
single source dosimetric uncertainties, sometimes manufactured
sources may differ from their design, so MC simulations is
recommended to be performed with representations of the final clinically
delivered product.
• While uncertainties as a topic have been receiving much more attention
over the years and the quantification of source construction effects
suffers from the lack of a routine clinical method to obtain source
specific average data, this work proposed a method for each dosimetry
investigator to estimate the overall dosimetric uncertainties related to a
specific source model and clinical protocol being studied.
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